JP2019513799A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019513799A5 JP2019513799A5 JP2018554487A JP2018554487A JP2019513799A5 JP 2019513799 A5 JP2019513799 A5 JP 2019513799A5 JP 2018554487 A JP2018554487 A JP 2018554487A JP 2018554487 A JP2018554487 A JP 2018554487A JP 2019513799 A5 JP2019513799 A5 JP 2019513799A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- fragment
- active ingredient
- extracellular matrix
- matrix component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 5
- 230000000699 topical effect Effects 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 11
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims 9
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims 9
- 210000002744 extracellular matrix Anatomy 0.000 claims 9
- 239000012634 fragment Substances 0.000 claims 9
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims 2
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 claims 2
- 108030001720 Bontoxilysin Proteins 0.000 claims 2
- 102000008186 Collagen Human genes 0.000 claims 2
- 108010035532 Collagen Proteins 0.000 claims 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 2
- 108010036949 Cyclosporine Proteins 0.000 claims 2
- 102000016942 Elastin Human genes 0.000 claims 2
- 108010014258 Elastin Proteins 0.000 claims 2
- 102000016359 Fibronectins Human genes 0.000 claims 2
- 108010067306 Fibronectins Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 102000004856 Lectins Human genes 0.000 claims 2
- 108090001090 Lectins Proteins 0.000 claims 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 2
- 230000003444 anaesthetic effect Effects 0.000 claims 2
- 230000000202 analgesic effect Effects 0.000 claims 2
- 230000000844 anti-bacterial effect Effects 0.000 claims 2
- 230000000843 anti-fungal effect Effects 0.000 claims 2
- 229940121375 antifungal agent Drugs 0.000 claims 2
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 claims 2
- 229960002470 bimatoprost Drugs 0.000 claims 2
- 229940053031 botulinum toxin Drugs 0.000 claims 2
- 229960001265 ciclosporin Drugs 0.000 claims 2
- 229920001436 collagen Polymers 0.000 claims 2
- 229930182912 cyclosporin Natural products 0.000 claims 2
- 229920002549 elastin Polymers 0.000 claims 2
- 229960002870 gabapentin Drugs 0.000 claims 2
- 229920002674 hyaluronan Polymers 0.000 claims 2
- 229960003160 hyaluronic acid Drugs 0.000 claims 2
- 229960000890 hydrocortisone Drugs 0.000 claims 2
- 239000002523 lectin Substances 0.000 claims 2
- 229960004194 lidocaine Drugs 0.000 claims 2
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 claims 2
- 229960004023 minocycline Drugs 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 229960001233 pregabalin Drugs 0.000 claims 2
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims 2
- 229960003471 retinol Drugs 0.000 claims 2
- 235000020944 retinol Nutrition 0.000 claims 2
- 239000011607 retinol Substances 0.000 claims 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims 2
- 229960001860 salicylate Drugs 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 claims 2
- 229960000835 tadalafil Drugs 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 2
- 201000004384 Alopecia Diseases 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 239000003086 colorant Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 208000024963 hair loss Diseases 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 239000003906 humectant Substances 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 239000002609 medium Substances 0.000 claims 1
- 239000004014 plasticizer Substances 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 239000000080 wetting agent Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662321626P | 2016-04-12 | 2016-04-12 | |
| US62/321,626 | 2016-04-12 | ||
| PCT/US2017/027275 WO2017180788A1 (en) | 2016-04-12 | 2017-04-12 | Compositions for topical application of compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019513799A JP2019513799A (ja) | 2019-05-30 |
| JP2019513799A5 true JP2019513799A5 (https=) | 2020-01-09 |
Family
ID=59999163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554487A Pending JP2019513799A (ja) | 2016-04-12 | 2017-04-12 | 化合物の局所適用を目的とした組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20170290778A1 (https=) |
| EP (1) | EP3442488A4 (https=) |
| JP (1) | JP2019513799A (https=) |
| KR (1) | KR20190022476A (https=) |
| CN (1) | CN109152702A (https=) |
| AU (1) | AU2017250267A1 (https=) |
| CA (1) | CA3020400A1 (https=) |
| IL (1) | IL262180B2 (https=) |
| MX (1) | MX2018012486A (https=) |
| SG (1) | SG11201808990QA (https=) |
| WO (1) | WO2017180788A1 (https=) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL152486A0 (en) | 2002-10-25 | 2003-05-29 | Meir Eini | Alcohol-free cosmetic and pharmaceutical foam carrier |
| SG160357A1 (en) * | 2005-03-03 | 2010-04-29 | Revance Therapeutics Inc | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
| US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
| EP2445521A4 (en) | 2009-06-25 | 2015-08-26 | Revance Therapeutics Inc | ALBUMINE-FREE BOTULINUM TOXIN FORMULATIONS |
| CA2769625C (en) | 2009-07-29 | 2017-04-11 | Foamix Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
| US10029013B2 (en) | 2009-10-02 | 2018-07-24 | Foamix Pharmaceuticals Ltd. | Surfactant-free, water-free formable composition and breakable foams and their uses |
| MX377365B (es) | 2016-09-08 | 2025-03-10 | Journey Medical Corp | Composiciones y métodos para tratar rosácea y acné. |
| BR112019004935A2 (pt) | 2016-09-13 | 2019-06-04 | Allergan, Inc. | composições de toxina clostridial não proteíca estabilizada |
| US11040090B2 (en) * | 2016-12-08 | 2021-06-22 | Prime Bio, Inc | Botulinum neurotoxin compositions |
| MY210233A (en) * | 2017-10-11 | 2025-09-04 | Illustris Pharmaceuticals Inc | Methods and compositions for topical delivery |
| WO2019118928A1 (en) | 2017-12-15 | 2019-06-20 | Tarsus Pharmaceuticals, Inc. | Isoxazoline parasiticide formulations and methods for treating blepharitis |
| KR102189632B1 (ko) * | 2018-03-09 | 2020-12-11 | 전남대학교산학협력단 | 신규 균주 페니실리움 애시둠 및 이의 용도 |
| KR101899413B1 (ko) * | 2018-05-03 | 2018-09-18 | 주식회사 케어사이드 | 피부 감염의 예방 또는 치료용 조성물 |
| JP7430140B2 (ja) | 2018-06-26 | 2024-02-09 | 久光製薬株式会社 | マイクロニードルデバイス及びそれを製造する方法 |
| KR102088104B1 (ko) * | 2018-06-29 | 2020-03-11 | 호서대학교 산학협력단 | 개망초 꽃 에센셜 오일을 포함하는 신경 근육 관련 질환 예방 및 치료용 조성물 |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| US12502377B2 (en) | 2019-04-04 | 2025-12-23 | Tarsus Pharmaceuticals, Inc. | Method of eradicating ticks that attach to humans using lotilaner formulations |
| CN111825775B (zh) * | 2019-04-18 | 2021-11-02 | 复旦大学 | 密枝圆柏多糖及其制备方法和在制备抗肿瘤药物中的用途 |
| CN110090193B (zh) * | 2019-05-14 | 2022-04-12 | 东方爱堡(北京)母婴健康科技有限公司 | 一种具有减脂功效的祛痘保湿精华液及其制备方法 |
| US20210000910A1 (en) | 2019-07-03 | 2021-01-07 | Jysk Skin Solutions Pte Ltd | Topical compositions |
| CN115279788A (zh) * | 2019-12-24 | 2022-11-01 | 黛芙生物科学公司 | 用于治疗银屑病和其他疾病的外用环孢霉素 |
| CN111281980B (zh) * | 2020-02-05 | 2025-01-24 | 芽米科技(广州)有限公司 | 一种水溶性γ-聚谷氨酸-替米考星复合物及其制备方法 |
| CN111110831B (zh) * | 2020-02-20 | 2023-08-08 | 柳州市工人医院 | 一种溃疡糊剂及其制备方法 |
| CN111297884B (zh) * | 2020-04-02 | 2021-03-30 | 中国农业科学院蜜蜂研究所 | 腺苷在蜜蜂病毒感染防治中的应用 |
| CN111329846A (zh) * | 2020-04-24 | 2020-06-26 | 云南伦扬科技有限公司 | 一种阴道杀菌贴膜及其制备方法 |
| CN111587861A (zh) * | 2020-05-21 | 2020-08-28 | 广州市穗升有害生物防治中心 | 引诱箱 |
| WO2023048748A1 (en) * | 2020-08-10 | 2023-03-30 | Ziropa, Inc. | Compositions and methods for topical delivery |
| WO2023080886A1 (en) * | 2020-09-29 | 2023-05-11 | Ziropa, Inc. | Compositions and methods for pain relief and numbing |
| JP2024519426A (ja) * | 2020-09-29 | 2024-05-14 | ジロパ・インコーポレイテッド | 疼痛の緩和及び麻痺のための組成物及び方法 |
| MX2023004648A (es) * | 2020-10-22 | 2023-05-18 | Pfizer | Suspensiones acuosas sin peg para administracion parenteral. |
| CN114617974B (zh) * | 2020-12-10 | 2023-10-03 | 中国科学院苏州纳米技术与纳米仿生研究所 | 一种多肽白蛋白纳米粒及其制备方法和应用 |
| HU231397B1 (hu) | 2021-01-22 | 2023-06-28 | Egis Gyógyszergyár Zrt. | Pregabalint tartalmazó topikális gyógyszerkészítmény |
| AU2022210856A1 (en) | 2021-01-22 | 2023-08-17 | Egis Gyógyszergyár Zrt. | Topical formulation containing modified phospholipid compounds |
| CA3172145A1 (en) * | 2021-02-05 | 2022-08-11 | Yelena Zolotarsky | Recombinant collagen skincare compositions and methods of use thereof |
| WO2022232161A1 (en) * | 2021-04-26 | 2022-11-03 | Sypherion, Llc | Inhibitors of nsp1 for treatment of sars-cov-2 |
| CN113332238A (zh) * | 2021-06-09 | 2021-09-03 | 四川恒通动保生物科技有限公司 | 一种加米霉素的复合溶液剂的制备方法 |
| JP7141025B1 (ja) * | 2021-11-11 | 2022-09-22 | エルデシエロ プライベート リミテッド | 化合物、組成物、方法、及び製造方法 |
| WO2023119230A1 (en) | 2021-12-22 | 2023-06-29 | L'oreal | Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use |
| CN117186177B (zh) * | 2022-05-31 | 2024-08-23 | 中国农业大学 | 一种具有降尿酸活性的鸭血球蛋白肽及其制备方法 |
| US12083204B2 (en) | 2022-06-02 | 2024-09-10 | L'oreal | Topical composition for homeostatic delivery of nitric oxide and uses thereof |
| WO2024007014A2 (en) * | 2022-06-30 | 2024-01-04 | Board Of Trustees Of The University Of Arkansas | Process for treating livestock exposed to toxic forage using melatonin compositions |
| CN117582442A (zh) * | 2022-08-18 | 2024-02-23 | 智泽童康(广州)生物科技有限公司 | 双嘧达莫在制备防治蚊虫叮咬的产品中的应用 |
| US12059430B2 (en) | 2022-09-29 | 2024-08-13 | Adora Animal Health Corporation | Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions |
| CN116098882A (zh) * | 2023-04-06 | 2023-05-12 | 山东诚创蓝海医药科技有限公司 | 一种含利多卡因丙胺卡因的组合物及其制备方法 |
| CN116791274B (zh) * | 2023-06-16 | 2026-03-27 | 福建恒安集团有限公司 | 一种超柔软爽滑纯棉无纺布的制备方法及其应用 |
| CN116870001B (zh) * | 2023-08-11 | 2024-08-27 | 云南中医药大学 | 吲哚-3-甲酸衍生物与氟康唑联合在制备抗耐药白念珠菌药物中的应用 |
| CN117427027B (zh) * | 2023-12-21 | 2024-04-23 | 舒芙雅生物科技有限公司 | 一种祛痘组合物及其制备方法 |
| US12357725B1 (en) | 2024-05-30 | 2025-07-15 | King Saud University | Clinical dressing loaded with coffee extract |
| CN120284984B (zh) * | 2025-04-25 | 2025-10-17 | 首都医科大学附属北京胸科医院 | 一种抗结核分枝杆菌感染的化合物及其应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5234914A (en) * | 1991-06-11 | 1993-08-10 | Patent Biopharmaceutics, Inc. | Methods of treating hemorrhoids and anorecial disease |
| IT1260148B (it) * | 1992-04-17 | 1996-03-28 | Fidia Spa | Impiego di preparazioni di acido ialuronico per la formazione di tessuto osseo |
| US8728510B1 (en) * | 2002-03-15 | 2014-05-20 | Advanced Cardiovascular Systems, Inc. | Biocompatible carrier containing a bioadhesive material |
| US7956180B2 (en) * | 2004-05-27 | 2011-06-07 | Novozymes A/S | Dried and agglomerated hyaluronic acid product |
| WO2006063021A2 (en) * | 2004-12-07 | 2006-06-15 | Surmodics, Inc. | Coatngs with crystallized active agents (s) |
| US7727537B2 (en) * | 2005-02-14 | 2010-06-01 | Dpm Therapeutics Corp. | Stabilized compositions for topical administration and methods of making same |
| CA2876767C (en) * | 2005-10-03 | 2018-07-10 | Mark A. Pinsky | Liposomes comprising hyaluronic acid and their use in improved skin care |
| JP5481197B2 (ja) * | 2006-12-26 | 2014-04-23 | ボミ・パテル・フラムローゼ | 高色素沈着した皮膚のための皮膚美白組成物 |
| WO2008124169A2 (en) * | 2007-04-10 | 2008-10-16 | The Trustees Of The University Of Pennsylvania | Islet cells composition and methods |
| US20100008878A1 (en) * | 2007-08-09 | 2010-01-14 | Foodchemifa Co., Ltd | Propylene glycol hyaluronate, and skincare preparation for external use comprising same |
| DE102008034265A1 (de) * | 2008-07-22 | 2010-01-28 | Beiersdorf Ag | Wirkstoffkombination aus Anisfruchtextrakt und Hyaluronsäure |
| KR101610985B1 (ko) * | 2008-11-14 | 2016-04-08 | 히스토젠, 인코포레이티드 | 암 치료를 위한 세포외 기질 조성물 |
| US8679470B2 (en) * | 2008-11-28 | 2014-03-25 | Luromed Llc | Composition using cross-linked hyaluronic acid for topical cosmetic and therapeutic applications |
| WO2010135449A1 (en) * | 2009-05-19 | 2010-11-25 | Plurogen Therapeutics, Inc. | Surface active agent compositions and methods for enhancing oxygenation, reducing bacteria and improving wound healing |
| US20110020271A1 (en) * | 2009-05-20 | 2011-01-27 | Humacyte, Inc. | Elastin for soft tissue augmentation |
| CA2703532C (en) * | 2010-05-10 | 2018-05-01 | Eva Turley | Topically administered, skin-penetrating glycosaminoglycan formulations suitable for use in cosmetic and pharmaceutical applications |
| US20110305737A1 (en) * | 2010-06-09 | 2011-12-15 | NY Derm LLC | Multi-Active Microtargeted Anti-Aging Skin Cream Polymer Technology |
| FR2971711B1 (fr) * | 2011-02-18 | 2014-06-13 | Isp Investments Inc | Composition cosmetique comprenant un extrait de petit epeautre en tant qu'agent activateur de la synthese des proteines de la matrice extracellulaire |
| WO2014134532A1 (en) * | 2013-02-28 | 2014-09-04 | Ventrix, Inc. | Methods and compositions for tissue therapy and analysis |
| US10337406B2 (en) * | 2013-02-28 | 2019-07-02 | United Technologies Corporation | Method and apparatus for handling pre-diffuser flow for cooling high pressure turbine components |
| WO2014138235A1 (en) * | 2013-03-05 | 2014-09-12 | Liberatoscioli Dante | Apparatus for relieving back pain |
-
2017
- 2017-04-12 AU AU2017250267A patent/AU2017250267A1/en not_active Abandoned
- 2017-04-12 US US15/486,240 patent/US20170290778A1/en not_active Abandoned
- 2017-04-12 CA CA3020400A patent/CA3020400A1/en not_active Abandoned
- 2017-04-12 MX MX2018012486A patent/MX2018012486A/es unknown
- 2017-04-12 IL IL262180A patent/IL262180B2/en unknown
- 2017-04-12 SG SG11201808990QA patent/SG11201808990QA/en unknown
- 2017-04-12 CN CN201780025623.6A patent/CN109152702A/zh active Pending
- 2017-04-12 JP JP2018554487A patent/JP2019513799A/ja active Pending
- 2017-04-12 EP EP17783085.8A patent/EP3442488A4/en not_active Withdrawn
- 2017-04-12 KR KR1020187032806A patent/KR20190022476A/ko not_active Ceased
- 2017-04-12 WO PCT/US2017/027275 patent/WO2017180788A1/en not_active Ceased
-
2018
- 2018-09-14 US US16/131,859 patent/US20190008795A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019513799A5 (https=) | ||
| US11666531B2 (en) | Delivery system | |
| JP5401457B2 (ja) | 抗菌ペプチド、組成物及びその使用方法 | |
| US9072747B2 (en) | Topical compositions and methods of treatment of anorectal disorders | |
| US10179159B2 (en) | Topical anesthetic formulation | |
| US9642895B2 (en) | Peptides for enhancing transdermal delivery | |
| Drake et al. | Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial | |
| AU2013289403B2 (en) | Diclofenac formulations | |
| JP2016527188A5 (https=) | ||
| EA200901112A1 (ru) | Жидкие композиции, образующие дермальные пленки, для введения лекарственных препаратов в кожу | |
| WO2014027006A1 (en) | Bioadhesive formulations for use in drug delivery | |
| US20210046040A1 (en) | Pain-relieving topical compositions | |
| US20160015818A1 (en) | Compositions and methods for physiological delivery using cannabidiol | |
| Aronson | Antifungal drugs |